Fig. 4

Effect of empagliflozin on the expression of markers of PERK and AKT pathway in LMNA R321X-cardiomyocytes. A MTT assay performed on LMNA R321X-cardiomyocytes upon 48 h incubation with empagliflozin at three different concentrations. Statistical analysis was performed on three independent experiments. Data reported as mean ± SEM and significance calculated by one-way Anova. B Representative Western blotting of p-PERK, CHOP, full length PARP (PARL-FL), cleaved PARP (PARP-CL) and p-AKT performed on lysates from LMNA R321X-cardiomyocytes treated with 10 µM empagliflozin for 48 h and from LMNA WT-cardiomyocytes as control. The triplicate of each experimental condition in the representative western blotting corresponds to three different biological replicas. C Densitometric analysis of the immunoreactive bands corresponding to p-PERK, CHOP, PARP-CL and p-AKT in the experimental conditions shown in B, normalized for total protein content and reported as % of the control condition (WT). Data are reported as mean ± SEM. Statistical analysis was performed on three independent experiments and significance calculated one-way ANOVA and Tukey's multiple comparisons test (°°p = 0.001 and °°°p = 0.0006 for WT vs R321X; **p = 0.007 for untreated R321X vs treated R321X)